118
0.00%
Close of 9 Nov 2026, in IDR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pyridam Farma Tbk PT
Its shares trade on IDX under the ticker PYFA.JK. It has been listed since 16 October 2001. In the fiscal year to 31 December 2025, it reported revenue of IDR 2.76trn and a net loss of IDR 379.67bn. At that date it held total assets of IDR 6.77trn and shareholders' equity of IDR 766.99bn.
PT Pyridam Farma Tbk engages in the production and development of pharmaceutical medicines, and trading of medical supplies. The company is headquartered in Jakarta, Dki Jakarta. The company went IPO on 2001-10-16. The firm is engaged in the production, development, and trade of pharmaceuticals, as well as the trade of medical devices and cosmetics. Its segments include pharmaceutical products, esthetic, and toll manufacturing services; and medical equipments. The company offers products across consumer health, pyfaesthetic, sanitizer and antiseptic, sterile/injection, biomedilab, betadine group and guardix, and medical support categories. The consumer health category provides over the counter drugs, including supplements and other preventive products, along with energy drinks and healthy ready-to-drink products. Its pyfaesthetic category includes products, such as Arosa Gel, A-Stark Gel, Hymen Gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb Gel. Its sterile/injection category is focused on injection products. Its biomedilab category provides various medical equipment and tools for hospital laboratories.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Oct 2001
- Employees
- 1,283
- Website
- pyfa.co.id ↗
Leadership
Pay as last reported
- Mr. Robby YuliantoPresident Commissioner
- Mr. Yan Gwan LeePresident Director
- Mr. Paulus Widjanarko BrotosaputroDirector
- Mr. Yenfrino GunadiDirector
- Dr. Augus VentyCommissioner
- Mr. Mohammad Syamsul ArifinIndependent Commissioner
- Mr. Andre SylvestreIndependent Commissioner
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Produces and develops pharmaceutical medicines and trades medical supplies
- Headquartered in Jakarta with 1,283 employees
- Offers diverse product categories including consumer health and medical equipment
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market position provided
- No information on competitive advantages or unique selling points
Opportunities
- Expansion into new markets for pharmaceutical products
- Growth in consumer health and medical equipment segments
- Potential for increased market share in pharmaceuticals
Threats
- Competition in the pharmaceutical industry
- Regulatory changes affecting pharmaceutical production
- Market volatility in the healthcare sector
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.